
Jan 11 (Reuters) - Regenxbio Inc RGNX.O:
REGENXBIO HIGHLIGHTS KEY 2026 CATALYSTS AND ANNOUNCES POSITIVE LONG-TERM FUNCTIONAL OUTCOMES IN LEAD DUCHENNE GENE THERAPY PROGRAM
REGENXBIO INC - NEW RGX-202 DATA SHOWS LONG-TERM EFFECT AT 18 MONTHS
REGENXBIO INC - EXPECTING FDA PDUFA DECISION AND DATA READOUTS IN 2026
REGENXBIO INC - TO RECEIVE $100 MILLION PAYMENT FROM ABBVIE IN 1H 2026
REGENXBIO INC - EXPECTS PIVOTAL TRIAL DATA IN Q4 2026